Ketogenic diet for adults in super-refractory status epilepticus. 2014

Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
From the Departments of Neurology (K.T.T., J.C.P., E.H.K., R.G.G., A.L.H., A.V., M.C.C.) and Pediatrics (E.H.K., A.L.H.), Johns Hopkins Hospital, Baltimore, MD; Department of Neurology (S.E.H.), Mayo Clinic, Rochester, MN; Department of Food and Nutrition Services (K.R.), Rush University Medical Center, Chicago, IL; Institute for Clinical and Translational Research (B.H.), Johns Hopkins University, Baltimore; Department of Neurology (P.W.K.), Johns Hopkins Bayview Medical Center, Baltimore; and Departments of Anesthesiology-Critical Care Medicine, Neurosurgery, and Medicine (R.G.G.), Johns Hopkins University School of Medicine, Baltimore, MD.

OBJECTIVE To describe a case series of adult patients in the intensive care unit in super-refractory status epilepticus (SRSE; refractory status lasting 24 hours or more despite appropriate anesthetic treatment) who received treatment with the ketogenic diet (KD). METHODS We performed a retrospective case review at 4 medical centers of adult patients with SRSE treated with the KD. Data collected included demographic features, clinical presentation, diagnosis, EEG data, anticonvulsant treatment, and timing and duration of the KD. Primary outcome measures were resolution of status epilepticus (SE) after initiation of KD and ability to wean from anesthetic agents. RESULTS Ten adult patients at 4 medical centers were started on the KD for SRSE. The median age was 33 years (interquartile range [IQR] 21), 4 patients (40%) were male, and 7 (70%) had encephalitis. The median duration of SE before initiation of KD was 21.5 days (IQR 28) and the median number of antiepileptic medications used before initiation of KD was 7 (IQR 7). Ninety percent of patients achieved ketosis, and SE ceased in all patients achieving ketosis in a median of 3 days (IQR 8). Three patients had minor complications of the KD including transient acidosis and hypertriglyceridemia and 2 patients ultimately died of causes unrelated to the KD. CONCLUSIONS We describe treatment of critically ill adult patients with SRSE with the KD, with 90% of patients achieving resolution of SE. Prospective trials are warranted to examine the efficacy of the KD in adults with refractory SE. METHODS This study provides Class IV evidence that for intensive care unit patients with refractory SE, a KD leads to resolution of the SE.

UI MeSH Term Description Entries
D007362 Intensive Care Units Hospital units providing continuous surveillance and care to acutely ill patients. ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013226 Status Epilepticus A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30) Absence Status,Complex Partial Status Epilepticus,Generalized Convulsive Status Epilepticus,Non-Convulsive Status Epilepticus,Petit Mal Status,Simple Partial Status Epilepticus,Grand Mal Status Epilepticus,Status Epilepticus, Complex Partial,Status Epilepticus, Electrographic,Status Epilepticus, Generalized,Status Epilepticus, Generalized Convulsive,Status Epilepticus, Grand Mal,Status Epilepticus, Non-Convulsive,Status Epilepticus, Simple Partial,Status Epilepticus, Subclinical,Electrographic Status Epilepticus,Generalized Status Epilepticus,Non Convulsive Status Epilepticus,Status Epilepticus, Non Convulsive,Status, Absence,Status, Petit Mal,Subclinical Status Epilepticus

Related Publications

Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
November 2017, Pediatric neurology briefs,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
October 2021, Neurology. Clinical practice,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
October 2016, Seizure,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
March 2018, Zhonghua er ke za zhi = Chinese journal of pediatrics,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
March 2020, Neurology,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
July 2012, Revista de neurologia,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
December 2015, Pediatrics and neonatology,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
May 2019, Brain & development,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
January 2023, Frontiers in molecular biosciences,
Kiran T Thakur, and John C Probasco, and Sara E Hocker, and Kelly Roehl, and Bobbie Henry, and Eric H Kossoff, and Peter W Kaplan, and Romergryko G Geocadin, and Adam L Hartman, and Arun Venkatesan, and Mackenzie C Cervenka
March 2022, Seizure,
Copied contents to your clipboard!